⁠InsideArbitrage
🚨 $MASI Masimo - Catherine Szyman appointed as CEO, effective Feb. 12, 2025. Michelle Brennan transitions from Interim CEO to Chair of the Board, with Quentin Koffey as Vice Chair.

💼Szyman’s Compensation: Szyman will receive an annual base salary of $1M, a target bonus of 100% of her salary, and a long-term incentive target of $7M.

🌪️ A Tumultuous Year: The leadership change follows a challenging year for Masimo, including founder Joe Kiani stepping down as CEO after a shareholder vote ousted him as Board Chair amid a proxy battle with Politan Capital Management.

✂️Masimo enacted layoffs at its headquarters in late 2024 as part of efforts to streamline operations and refocus on growth

🎯 Ms. Szyman led the Critical Care business at Edwards Lifesciences for over a decade – including through the acquisition by BD (Becton, Dickinson and Company) in September of 2024. Szyman also serves on the board of Inari Medical and previously on Outset Medical.

📈 Masimo's stock is up 40% over the past year.
tweet

⁠InsideArbitrage
The acquisition of Smartsheet $SMAR by Blackstone $BX and Vista Equity Partners was completed on January 22, 2025. It took 120 days for the deal to be completed.
tweet

⁠Dimitry Nakhla | Babylon Capital®
10 Stocks EPS CAGR >12% Last 5 Years & Forward 3-Year EPS CAGR >12% 💸

📦 Amazon $AMZN
•5-Year EPS CAGR: 35%
•Forward EPS CAGR: 21%

🧬 Novo Nordisk $NVO
•5-Year EPS CAGR: 23%
•Forward EPS CAGR: 15%

🤖 Nvidia $NVDA
•5-Year EPS CAGR: 82%
•Forward EPS CAGR: 28%

☁️ Alphabet $GOOG
•5-Year EPS CAGR: 25%
•Forward EPS CAGR: 14%

📊 Intuit $INTU
•5-Year EPS CAGR: 20%
•Forward EPS CAGR: 14%

💳 Visa $V
•5-Year EPS CAGR: 13%
•Forward EPS CAGR: 12%

💵 Mastercard $MA
•5-Year EPS CAGR: 13%
•Forward EPS CAGR: 15%

📸 Meta Platforms $META
•5-Year EPS CAGR: 21%
•Forward EPS CAGR: 13%

☀️ ASML Holding $ASML
•5-Year EPS CAGR: 25%
•Forward EPS CAGR: 24%

🏦 Fair Isaac $FICO
•5-Year EPS CAGR: 26%
•Forward EPS CAGR: 24%
tweet

⁠Stock Analysis Compilation
Nightview Capital on Netflix $NFLX US

Thesis: Netflix is leveraging its streaming leadership to expand into advertising and live events, with strong subscriber growth and operational excellence, indicating significant future growth potential.

(Extract from their Q4 letter) https://t.co/gQYxZRrYne
tweet

⁠Investing visuals
Netflix $NFLX posted a strong quarter and is up +12% today.

Here's everything you need to know about $NFLX after its Q4'24 results👇 https://t.co/XqqCiTSooR
tweet

⁠InsideArbitrage
Sonim Technologies $SONM Forms Special Committee to Evaluate Strategic Alternatives -
🛜Mike Mulica will chair the committee, which includes Mulica and James Cassano.
🛜In consultation with its advisors, including Roth Capital Partners, the committee will carefully review strategic alternatives from several parties, including, but not limited to, Orbic North America.
🛜The committee will consider various strategic options, including business combinations such as mergers or acquisitions and other potential transactions, such as selling the company or a significant portion of its assets.
tweet

⁠Quiver Quantitative
NEW: We just released a live feed that gives alerts on:

- Politicians' trading
- Government contracts
- Corporate lobbying
- Insider trading
- Hedge fund activity
- Company press releases

See below: https://t.co/MwovaXDshC
tweet

⁠Dimitry Nakhla | Babylon Capital®
I’ve decided to begin accumulating shares of $NVO here at $79-$82 initial 3% position with a targeted ~5% allocation 🧬

Here’s why:

Despite recent negative sentiment and a sharp drop in share price, $NVO fundamentals remain strong 👇🏽

•Double-digit EPS growth
•History of strong returns on capital
•Innovation-led corporate culture
•Aggressive share buybacks
•Attractive valuation relative to growth
•AA- S&P Credit Rating
•$11.2B in cash & $7.7B in long-term debt
___

IF $NVO drops to $65 it’s a win-win as I get to build a full position with $NVO trading for 18x NTM EPS (which would be a rare multiple to pay for $NVO, a level not seen since 2018-2019 & well below its 10-Year average multiple of 25x)

Outsized returns in biotech often follow a familiar pattern: adverse news creates a buying opportunity, allowing investors to accumulate shares with a margin of safety when expectations have been significantly reduced. (e.g. $ABBV at $70 in 2019 & $VRTX at $200 in 2021)

Novo Nordisk $NVO stock is currently trading near its lowest valuation multiple in the past 5 years 🧬

Notably, the only time it was lower was during the pandemic-driven stock market sell-off in March 2020 https://t.co/RvvOxB7h1H - Dimitry Nakhla | Babylon Capital®
tweet

⁠Investing visuals
$NU Mexico has reached 10 Million Customers, 5 years after launching its first product.

What their total customer growth looks like over the past years👇👌 https://t.co/hoVwJy6LGh
tweet

⁠Quiver Quantitative
RT @QuiverCongress: JUST IN: Senator Ed Markey just introduced legislation to ban fossil fuel lobbyists and execs from heading energy departments for a 10-year period.

Do you support this? https://t.co/mz8kcpyQXE
tweet